Medtronic PLC $MDT Stake Boosted by BTC Capital Management Inc.

Posted by Stanley Muller on Jun 25th, 2026

BTC Capital Management Inc. boosted its stake in shares of Medtronic PLC (NYSE:MDT – Free Report) by 33.2% during the 1st quarter, Holdings Channel.com reports. The institutional investor owned 72,184 shares of the medical technology company’s stock after purchasing an additional 18,006 shares during the quarter. BTC Capital Management Inc.’s holdings in Medtronic were worth $6,252,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Lodestone Wealth Management LLC purchased a new position in shares of Medtronic in the fourth quarter worth approximately $27,000. Anfield Capital Management LLC lifted its position in shares of Medtronic by 410.7% in the 4th quarter. Anfield Capital Management LLC now owns 286 shares of the medical technology company’s stock valued at $27,000 after acquiring an additional 230 shares in the last quarter. Monetary Solutions Ltd purchased a new stake in shares of Medtronic in the 4th quarter valued at approximately $27,000. Board of the Pension Protection Fund acquired a new position in Medtronic in the 4th quarter worth approximately $29,000. Finally, GoalVest Advisory LLC acquired a new position in Medtronic in the 4th quarter worth approximately $29,000. 82.06% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts have issued reports on MDT shares. TD Cowen reissued a “buy” rating and set a $119.00 target price on shares of Medtronic in a research note on Thursday, June 4th. Wells Fargo & Company decreased their target price on Medtronic from $114.00 to $102.00 and set an “overweight” rating for the company in a research report on Thursday, June 4th. The Goldman Sachs Group lowered their price target on Medtronic from $84.00 to $83.00 and set a “neutral” rating on the stock in a report on Thursday, June 4th. Robert W. Baird dropped their price target on Medtronic from $93.00 to $85.00 and set a “neutral” rating on the stock in a research report on Thursday, June 4th. Finally, Leerink Partners reduced their price objective on Medtronic from $117.00 to $104.00 and set an “outperform” rating for the company in a research note on Thursday, June 4th. Seventeen investment analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the stock. According to data from MarketBeat.com, Medtronic currently has a consensus rating of “Moderate Buy” and an average price target of $99.00.

View Our Latest Research Report on Medtronic

Insiders Place Their Bets

In other Medtronic news, EVP Harry Skip Kiil sold 4,189 shares of the company’s stock in a transaction dated Monday, June 8th. The stock was sold at an average price of $80.44, for a total value of $336,963.16. Following the transaction, the executive vice president directly owned 37,227 shares of the company’s stock, valued at $2,994,539.88. This represents a 10.11% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.26% of the stock is currently owned by insiders.

Medtronic Stock Down 0.6%

MDT stock opened at $80.16 on Thursday. The company has a 50 day moving average of $79.67 and a two-hundred day moving average of $89.95. The company has a market cap of $102.61 billion, a price-to-earnings ratio of 21.49, a PEG ratio of 2.16 and a beta of 0.58. Medtronic PLC has a 12-month low of $73.31 and a 12-month high of $106.33. The company has a quick ratio of 1.87, a current ratio of 2.13 and a debt-to-equity ratio of 0.52.

Medtronic (NYSE:MDT – Get Free Report) last posted its quarterly earnings results on Wednesday, June 3rd. The medical technology company reported $1.55 EPS for the quarter, beating the consensus estimate of $1.54 by $0.01. Medtronic had a net margin of 13.20% and a return on equity of 14.51%. The business had revenue of $9.81 billion for the quarter, compared to analysts’ expectations of $9.62 billion. During the same period in the previous year, the company posted $1.62 EPS. Medtronic’s revenue was up 9.9% on a year-over-year basis. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. On average, equities analysts anticipate that Medtronic PLC will post 5.94 earnings per share for the current fiscal year.

Medtronic Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, July 17th. Shareholders of record on Friday, June 26th will be paid a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a yield of 3.6%. This is an increase from Medtronic’s previous quarterly dividend of $0.71. The ex-dividend date is Friday, June 26th. Medtronic’s dividend payout ratio is presently 76.14%.

Medtronic Profile

(Free Report)

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).